Eltropolamine API

Name	Eltropolamine
Chinese name	艾曲泊帕乙醇胺
Cas Number	496775-62-3
Source	India
Qualifications	USDMF/-/-/-/-

Eltropolone was developed by GlaxoSmithKline. The drug is a once-daily oral thrombopoietin (TPO) receptor agonist that stimulates the proliferation and differentiation of bone marrow stem cells and increases blood platelet levels. Altrobopar was originally approved by the US FDA for the treatment of thrombocytopenia in patients with chronic idiopathic thrombocytopenic purpura on November 20, 2008. In February 2014, it received the FDA breakthrough treatment for aplastic anemia. Qualified, has been approved in more than 100 countries around the world for the treatment of adult thrombocytopenia associated with chronic immune (idiopathic) thrombocytopenic purpura that is not applicable to other therapies, and is approved for use in 45 countries around the world Treatment of severe aplastic anemia (SAA) patients with insufficient response to immunosuppressive therapy (IST). The drug is also approved for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC) in 50 countries around the world. Studies have confirmed that this product can produce tertiary hematopoiesis in some patients with aplastic anemia, increasing the platelet count, red blood cell count and white blood cell count.

Hot Tags: eltropolamine api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Pleasant API, Rasagiline Mesylate API, Edoxaban API, Aprepitant Aprepitant API, Apremilast API, Perindopril Tert butylamine Salt API

• Previous: Acotiamide API
• Next: Mesalazine API